What are the Therapeutic Implications of Receptor Targeting?
Targeting receptor abnormalities has become a cornerstone of modern cancer therapy. Targeted therapies like tyrosine kinase inhibitors (TKIs) and monoclonal antibodies have shown significant efficacy in treating cancers with specific receptor abnormalities. For example, imatinib targets the BCR-ABL fusion protein in chronic myeloid leukemia, while trastuzumab targets HER2 in breast cancer. Additionally, hormone therapies targeting ER and AR are effective in treating hormone-sensitive cancers.
